Sign up to our newsletter Subscribe
Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries

Sign up to our newsletter Subscribe
New medicines lead to improved patient outcomes and societal benefits, but R&D is a long and costly process. Ongoing health economics research aims to find the right balance between incentivising manufacturers to innovate and ensuring affordable access for health systems.
An error has occurred, please try again later.